Penn Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Penn Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-439,790	Closed	-$8.72M	–	289
2015 Q3	$8.72M	Buy	439,790 +38,013	+9%	+$1.2M	0.46%	77
2015 Q2	$14M	Sell	401,777 -178,474	-31%	-$5.45M	0.58%	56
2015 Q1	$15.1M	Buy	+580,251	New	+$10.6M	0.59%	53

Other funds holding HZNP

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Lone Pine Capital Greenwich, Connecticut $16.4B AUM 99.7% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Penn Capital Management's HZNP Position: Q4 2015 in Review

Penn Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2015, closing a stake of 439,790 shares — an estimated $8.72M sold.

Penn Capital Management first reported a position in HZNP in Q1 2015 and held it in 3 quarters. The position peaked at $15.1M in Q1 2015. 202 funds tracked by Wall St. Rank hold HZNP as of Q4 2015.

Penn Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2015 after selling out during the quarter.
Penn Capital Management sold 439,790 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2015, an estimated $8.72M.
Penn Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2015 and held it in 3 quarters.
Penn Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $15.1M in Q1 2015.
202 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2015.

Based on Penn Capital Management's 13F filing for Q4 2015, filed 3 Feb 2016.